Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 782 participants.

Also called NCT03900026

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 782 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03900026
Other papers using this trial's data
  • Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial Lancet (London, England), 2025-09-20 DOI, PubMed 40907505

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Canada, Hungary (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03900026. Randomized; quadruple masking; primary purpose prevention. Start 2019-05-30 (actual); primary completion 2025-01-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
Acronym
NEWTON-CABG
Condition
Coronary Artery Bypass Graft Surgery
Condition
Atherosclerosis
Condition
Vein Occlusion
Intervention (Drug)
Evolocumab
Intervention (Other)
Placebo
Lead sponsor
Unity Health Toronto (class: other)
Collaborator
Applied Health Research Centre (class: other)

Record details

Record id
cardio:ct-nct03900026
Content hash
fea01e46208819a5bf1d4e4bd079dfe9fe47c7b307a440e411ea2a357d15823c